MedTrace Logo

Comparison Between GLP 1 Analogues and DPP 4 Inhibitors in Type 1 Diabetes Mellitus

NCT01235819 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2016-07-27

No results posted yet for this study

Summary

To study the effects of GLP 1 analogues and DPP 4 inhibitors on newly detected type 1 diabetes patients.

Conditions

Interventions

DRUG

Insulin

Exenatide Sitagliptin

DRUG

Sitagliptin

Sitagliptin 100 mg per day oral

DRUG

Exenatide

Exenatide 10 micrograms daily twice

Sponsors & Collaborators

  • Command Hospital, India

    lead OTHER_GOV

Principal Investigators

  • The Commandant, MD · Command Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
12 Years
Max Age
30 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-11-30
Primary Completion
2011-09-30
Completion
2011-09-30

Countries

  • India

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01235819 on ClinicalTrials.gov